ARIA Ariad Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the schedule of several data presentations on Iclusig® (ponatinib) that will take place at the 55th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, December 7 to 10, 2013. The schedule and meeting location for the sessions at ASH, together with the abstract information are listed below:

PACE Trial: Two-Year Follow Up in Chronic Phase Patients

  Title: Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 2-Year Follow-Up of the PACE Trial Oral Session: Chronic Myeloid Leukemia – Therapy: Emerging Aspects of Monitoring and Long Term Treatments Date & Time: Monday, December 9, 2013, 4:45 p.m. Abstract No.: 650 Presenter: Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center) Location: Hall E, Room E3  

PACE Trial: Management of Adverse Events

  Title: Ponatinib in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management of Adverse Events (AEs) Poster Session: Chronic Myeloid Leukemia - Therapy: Poster I Date & Time: Saturday, December 7, 2013, 5:30 – 7:30 p.m. Abstract No.: 1496 Author: Philipp D. Le Coutre, M.D. (Charité-Universitätsmedizin Berlin) Location: Hall E  

PACE Trial: Post-Dasatinib Efficacy and Safety

  Title: Efficacy and Safety of Ponatinib Following Failure of Dasatinib in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) in the PACE Trial Poster Session: Chronic Myeloid Leukemia - Therapy: Poster I Date & Time: Saturday, December 7, 2013, 5:30 – 7:30 p.m. Abstract No.: 1498 Author: Andreas Hochhaus, M.D. (University Medical Center Jena in Germany) Location: Hall E  

PACE Trial: Post-Nilotinib Efficacy and Safety

  Title: Efficacy and Safety of Ponatinib Following Failure of Nilotinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) in the PACE Trial Poster Session: Chronic Myeloid Leukemia - Therapy: Poster II Date & Time: Sunday, December 8, 2013, 6:30 – 8:30 p.m. Abstract No.: 2738 Author:

Hagop M. Kantarjian, M.D. (The University of Texas MD Anderson Cancer Center)

Location: Hall E  

PACE Trial: Baseline BCR-ABL Mutations Identified by Mass Spectrometry

  Title: Additional BCR-ABL1 Mutations Identified by Sensitive Mass Spectrometry in Chronic Phase CML Patients with T315I Treated with Ponatinib Are Associated with Relatively Inferior Responses and Outcomes Oral Session: Chronic Myeloid Leukemia - Therapy: Emerging Aspects of Monitoring and Long Term Treatments Date & Time: Monday, December 9, 2013 at 5:00 p.m. Abstract No.: 651 Presenter: Wendy T. Parker, Ph.D. (Department of Genetics and Molecular Pathology, Centre for Cancer Biology, Adelaide, Australia) Location: Hall E, Room E3  

PACE Trial: Baseline BCR-ABL Mutations Identified by Next-Generation Sequencing

  Title: Impact of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, on Ponatinib Response and End of Treatment (EOT) Mutation Analysis in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Oral Session: Chronic Myeloid Leukemia - Therapy: Emerging Aspects of Monitoring and Long Term Treatments Date & Time: Monday, December 9, 2013, 5:15 p.m. Abstract No.: 652

Presenter:

 

Michael Deininger, M.D., Ph.D. (University of Utah School of Medicine Huntsman Cancer Institute)

Location: Hall E, Room E3  

PACE Trial: Dose Modification

  Title: Clinical Impact of Dose Modification on Response to Ponatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Poster Session: Chronic Myeloid Leukemia - Therapy: Poster III Date & Time: Monday, December 9, 2013, 6:00 – 8:00 p.m. Abstract No.: 4007 Presenter: Javier Pinilla-Ibarz, M.D., Ph.D. (H. Lee Moffitt Cancer Center) Location: Hall E  

Investigator Sponsored Trial: MD Anderson’s Front Line Study

  Title: Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Poster Session: Chronic Myeloid Leukemia - Therapy: Poster I Date & Time: Saturday, December 7, 2013, 5:30 – 7:30 p.m. Abstract No.: 1483 Presenter: Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center) Location: Hall E  

Health Economics and Outcomes Research: Comparative Efficacy after 2G TKIs

  Title: Comparative Efficacy among Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of 2nd Generation Tyrosine Kinase Inhibitors (2G TKIs) Poster Session: Chronic Myeloid Leukemia - Therapy: Poster III Date & Time: Monday, December 9, 2013, 6:00 – 8:00 p.m. Abstract No.: 4010 Presenter: Jeff H. Lipton, Ph.D., M.D. (Princess Margaret Hospital, Toronto) Location: Hall E  

Preclinical: Potency of Ponatinib and Other Approved TKIs

  Title: Comprehensive Analysis of the In Vitro Potency of Ponatinib and All Other Approved BCR-ABL TKIs Against a Panel of Clinically-Relevant Single and Compound BCR-ABL Mutants Poster Session: Chronic Myeloid Leukemia - Therapy: Poster III Date & Time: Monday, December 9, 2013, 6:00 – 8:00 p.m. Abstract No.: 3992 Presenter: Joseph M. Gozgit, Ph.D. (ARIAD Pharmaceuticals, Inc.) Location: Hall E

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

ARIAD PharmaceuticalsFor InvestorsKendra Adams, 617-503-7028Kendra.adams@ariad.comorFor MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.com